SYMPLICITY™ BLOOD PRESSURE PROCEDURE
About the Symplicity procedure
Move beyond the barriers of high blood pressure (hypertension) with the Medtronic Symplicity blood pressure procedure, which offers a single, minimally invasive approach.
What makes the procedure different from traditional treatments?
- Proven safe and effective1–3
- Keeps working 24 hours a day — like a pill you never have to remember to take2,3
Adverse events include, but are not limited to, bruising and pain. Results may vary.
↓ 16.7
mmHg
In a three-year study of people who received the procedure, it helped reduce BP by 16.7 mmHg.1
The procedure explained.
Get a brief rundown of the Symplicity blood pressure procedure.
Explore
the science.
Learn more about how the Symplicity blood pressure procedure can help get your numbers down.1–3
Beyond basic treatments for
high blood pressure
See what happens during the Symplicity blood pressure procedure.
Set your
expectations.
Important information about the benefits and risks of the Symplicity blood pressure procedure
Another way to lower your blood pressure
Find out what to expect during the day of your Symplicity blood pressure procedure.
Finally finding blood pressure control
Hear how the Symplicity blood pressure procedure made a difference in a patient’s life.
These are individual experiences. Their thoughts and opinions are their own. Not everyone will experience the same results.
Find more answers.
Dive into our FAQ about the Symplicity blood pressure procedure.
References
1
Mahfoud F, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. Presented at euroPCR 2023. Includes Symplicity Spyral™ and Flex catheters.
2
Kandzari et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. Journal of the American College of Cardiology. 2023;82(19):1809–1823.
3
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. May 2, 2020;395(10234):1444–1451.